FY2026 EPS Estimates for Precigen Decreased by HC Wainwright

Precigen, Inc. (NASDAQ:PGEN - Free Report) - Stock analysts at HC Wainwright lowered their FY2026 earnings per share estimates for Precigen in a research note issued to investors on Thursday, January 23rd. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings of ($0.01) per share for the year, down from their previous forecast of $0.01. HC Wainwright currently has a "Buy" rating and a $6.00 price target on the stock. The consensus estimate for Precigen's current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for Precigen's FY2027 earnings at $0.20 EPS and FY2029 earnings at $0.62 EPS.

Separately, JMP Securities reissued a "market outperform" rating and set a $5.00 price objective on shares of Precigen in a research report on Tuesday, January 14th. Two analysts have rated the stock with a sell rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $7.00.

Precigen Stock Up 3.4 %

Shares of NASDAQ PGEN traded up $0.05 during trading on Friday, reaching $1.39. The company had a trading volume of 1,679,509 shares, compared to its average volume of 2,271,409. The business's 50-day moving average is $0.93 and its 200 day moving average is $1.06. The stock has a market cap of $405.62 million, a PE ratio of -2.52 and a beta of 1.65. Precigen has a 12-month low of $0.65 and a 12-month high of $1.93.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. LexAurum Advisors LLC raised its stake in Precigen by 151.9% during the 4th quarter. LexAurum Advisors LLC now owns 691,544 shares of the biotechnology company's stock valued at $775,000 after buying an additional 417,055 shares during the last quarter. SG Americas Securities LLC increased its position in Precigen by 27.9% during the fourth quarter. SG Americas Securities LLC now owns 57,641 shares of the biotechnology company's stock valued at $65,000 after acquiring an additional 12,578 shares during the last quarter. Synovus Financial Corp increased its position in Precigen by 100.0% during the third quarter. Synovus Financial Corp now owns 98,130 shares of the biotechnology company's stock valued at $93,000 after acquiring an additional 49,065 shares during the last quarter. Barclays PLC lifted its holdings in Precigen by 190.4% in the third quarter. Barclays PLC now owns 189,353 shares of the biotechnology company's stock valued at $179,000 after acquiring an additional 124,141 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Precigen by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company's stock valued at $3,075,000 after purchasing an additional 149,829 shares during the period. Institutional investors own 33.51% of the company's stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.